Drug pricing policy is rapidly shifting as elements of the U.S. Inflation Reduction Act, the One Big Beautiful Bill Act and President Trump’s Most Favored Nation pricing scheme converge to reshape payer behavior, commercial strategy, and access for specialty therapies. In this complimentary webinar, pricing and market access experts will look beyond the headlines to explain what is changing and what manufacturers should expect over the next two to three years. The discussion will cover IRA-driven price compression, Part D redesign, OBBBA-related volatility, and MFN’s impact on global-to-U.S. pricing corridors. Drawing on Clarivate real-world data and payer insights, the webinar will highlight early signals such as tighter formulary controls, increased utilization management and launch resequencing driven by pricing risk. Attendees will get a clearer understanding of:
Jennifer Snow is the founder of Apteka Policy, where she translates U.S. pharmaceutical policy into strategic clarity for drug manufacturers, coalitions, and advocacy organizations. Her work spans drug pricing, Medicare, Medicaid, 340B, the IRA, and PBMs with a focus on what leaders need to act on and what they can safely ignore.
